SB-649,868
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Identifiers | |
| ATC code | None |
| PubChem | CID 25195495 |
| ChemSpider | 25069706 |
| ChEMBL | CHEMBL1272307 |
| Chemical data | |
| Formula | C26H24FN3O3S |
| Mol. mass | 477.549 g/mol (free base) |
|
|
|
|
SB-649,868 is an orexin receptor antagonist in development by GlaxoSmithKline.[1][2] Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Merck & Co's suvorexant.[citation needed]
[edit] References
- ^ Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metab. Dispos. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199.
- ^ Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R (August 2012). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". J. Psychopharmacol. (Oxford) 26 (8): 1058–70. doi:10.1177/0269881111408954. PMID 21730017.
[edit] Further reading
- Ratti E (December 13, 2007). "Psychiatry: An Innovative Drug Discovery Pipeline" (GSK Neurosciences seminar). Archived from the original on December 5, 2008.
- Scammell TE, Winrow CJ (February 2011). "Orexin receptors: pharmacology and therapeutic opportunities". Annu. Rev. Pharmacol. Toxicol. 51: 243–66. doi:10.1146/annurev-pharmtox-010510-100528. PMC 3058259. PMID 21034217.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
